Recent inspection trends reinforce a fundamental principle: organisations cannot control risks that they cannot see. Data integrity failures, supply chain vulnerabilities, and system fragmentation all point to the same underlying issue—insufficient visibility into the true state of operations.
The TGA Compliance Principles for 2026 and 2027 reflect a proactive, risk-based approach to safeguarding public health through the regulation of therapeutic goods.
For therapeutic goods, biotechnology, and medical device startups, securing funding is not simply a matter of demonstrating innovative science. Investors require evidence of robust governance, clear regulatory pathways, and effective risk management.
May 2026 be a year of innovation, regulatory excellence, and continued progress in improving patient outcomes worldwide.